Ullmann Michael H
Known title: Exec VP, General CounselCIK: 0001537710
Associated companies
Transaction History
| JNJ | ▲ Buy | Option Exercise | 13,186 | $0 | 2/15/2022 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 6,209 | $1.0M | 2/15/2022 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 2,407 | $0 | 2/14/2022 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 871 | $147K | 2/14/2022 | View on chart |
| JNJ | ▼ Sell | Gift | 608 | $0 | 6/9/2021 | View on chart |
| JNJ | ▼ Sell | Gift | 304 | $0 | 6/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Johnson & Johnson: Key Takeaways for Long-Term Investors
Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.
Johnson & Johnson: Key Takeaways for Long-Term Investors. Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.